Skip to main content
. 2019 Aug 9;98(32):e16490. doi: 10.1097/MD.0000000000016490

Figure 3.

Figure 3

The level of carcinoembryonic antigen and cytokeratin-19 fragments. After nivolumab combined with chemotherapy is administered, the serum tumor marker level continues to reduce. Nivolumab was administered (green arrows); nivolumab combined with S1 was given (red arrows); nivolumab combined with SOX was given (blue arrows).